11/21
10:00 am
syre
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation
Low
Report
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation
11/20
10:00 am
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
11/20
10:00 am
syre
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out
Low
Report
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out
11/19
03:15 pm
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
11/18
09:18 pm
syre
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
Medium
Report
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
11/18
04:14 pm
syre
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
Medium
Report
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
11/13
08:05 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Robert W. Baird from $50.00 to $65.00. They now have an "outperform" rating on the stock.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Robert W. Baird from $50.00 to $65.00. They now have an "outperform" rating on the stock.
11/12
07:30 am
syre
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-a4ß7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential f
High
Report
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-a4ß7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential f
11/11
04:15 pm
syre
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-a4ß7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 [Yahoo!
High
Report
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-a4ß7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024 [Yahoo!
11/11
04:05 pm
syre
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-a4ß7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
Medium
Report
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-a4ß7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
11/8
10:05 pm
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
Low
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
11/7
05:07 pm
syre
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/7
04:05 pm
syre
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/1
04:44 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Medium
Report
Spyre Therapeutics Announces Grants of Inducement Awards
10/30
04:05 pm
syre
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
Medium
Report
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
10/29
11:33 am
syre
Demand For Innovative Therapies for Chronic Illnesses is set to Drive Growth in the Biologics Market is projected to reach USD 817.48 Billion by 2032, growing at a CAGR of 8.5% | FMI [Yahoo! Finance]
Low
Report
Demand For Innovative Therapies for Chronic Illnesses is set to Drive Growth in the Biologics Market is projected to reach USD 817.48 Billion by 2032, growing at a CAGR of 8.5% | FMI [Yahoo! Finance]
10/25
03:39 pm
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Guggenheim from $50.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Guggenheim from $50.00 to $65.00. They now have a "buy" rating on the stock.
10/14
08:00 am
syre
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
Medium
Report
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
10/4
05:00 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Medium
Report
Spyre Therapeutics Announces Grants of Inducement Awards
10/1
08:00 am
syre
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
Medium
Report
Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
9/10
04:58 pm
syre
Spyre Therapeutics to Participate in Upcoming Investor Conference [Yahoo! Finance]
Low
Report
Spyre Therapeutics to Participate in Upcoming Investor Conference [Yahoo! Finance]
9/10
04:47 pm
syre
Spyre Therapeutics to Participate in Upcoming Investor Conference
Low
Report
Spyre Therapeutics to Participate in Upcoming Investor Conference
9/4
08:37 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wedbush. They set an "outperform" rating and a $45.00 price target on the stock.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wedbush. They set an "outperform" rating and a $45.00 price target on the stock.